{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:38:59Z","timestamp":1791952739834,"version":"4.3.4"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100010318","name":"University of Manitoba","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010318","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shared Health"},{"name":"National Microbiology Laboratory"},{"name":"Avir Pharma Inc."},{"name":"Iterum Therapeutics"},{"DOI":"10.13039\/501100015631","name":"Merck Canada Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015631","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Paladin Labs"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023517","name":"Sandoz Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023517","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shionogi Inc."},{"name":"Sunovion Pharmaceuticals Canada Inc."},{"name":"Venatorx Pharmaceuticals Inc."},{"name":"Verity Pharmaceuticals and Xediton Pharmaceuticals Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To review phenotypic and genotypic characteristics of ertapenem-resistant Enterobacterales isolates identified by the CANWARD study from 2007 to 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Bacterial isolates were collected as part of the CANWARD surveillance study from 2007 to 2023. CLSI M7 broth microdilution antimicrobial susceptibility testing (12th edition, 2024) was performed. MICs were interpreted by CLSI M100 breakpoints (34th edition, 2024). WGS was performed to identify antimicrobial resistance markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Only 134 (0.7%) of the 19\u200a642 Enterobacterales were ertapenem-resistant. Carbapenemase producing Enterobacterales (CPE) accounted for 17.9% (n\u200a=\u200a24) of ertapenem-resistant isolates and were predominantly Klebsiella pneumoniae (54.2%) and Escherichia coli (20.8%). KPC was the most common carbapenemase identified (62.5%). K. pneumoniae ST834, ST16 and ST258, and E. coli ST131 were the most frequent STs detected. CPE percent resistant values ranged from 20.8% to 25.0% for ceftazidime\/avibactam, imipenem\/relebactam and meropenem\/vaborbactam. Most non-CPE ertapenem-resistant isolates were Enterobacter spp. (51.8%), E. coli (15.5%) and K. pneumoniae (10.9%). Non-CPE STs were most commonly E. cloacae ST108, ST50 and ST133, and E. coli ST131. Non-CPE percent resistant values ranged from 2.7% to 4.5% for ceftazidime\/avibactam, imipenem\/relebactam and meropenem\/vaborbactam. At least one of an AmpC, an ESBL or porin alternations were observed in most non-CPE isolates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In Canada, ertapenem-resistant Enterobacterales remain uncommon (0.7%). CPE isolates demonstrated higher percent resistant values for multiple antimicrobial classes and harboured more antimicrobial resistance genes than non-CPE isolates. Continued monitoring for ertapenem-resistant Enterobacterales, particularly CPE, is important given their associated multidrug resistance to both established and newer agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf221","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T07:38:35Z","timestamp":1750750715000},"page":"ii54-ii61","source":"Crossref","is-referenced-by-count":4,"title":["Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007\u201323)"],"prefix":"10.1093","volume":"80","author":[{"given":"Laura F","family":"Mataseje","sequence":"first","affiliation":[{"name":"National Microbiology Laboratory, Public Health Agency of Canada , 1015 Arlington Street, Winnipeg, Manitoba R3E 3M4 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7914-9198","authenticated-orcid":false,"given":"Nicole","family":"Lerminiaux","sequence":"additional","affiliation":[{"name":"National Microbiology Laboratory, Public Health Agency of Canada , 1015 Arlington Street, Winnipeg, Manitoba R3E 3M4 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5826-2869","authenticated-orcid":false,"given":"Philippe","family":"Lagac\u00e9-Wiens","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba , Room 543-745 Bannatyne Avenue, Winnipeg Manitoba R3E 0J9 ,","place":["Canada"]},{"name":"Clinical Microbiology, Diagnostic Services, Shared Health , MS673-820 Sherbrook Street, Winnipeg, Manitoba R3A 1R9 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Walkty","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba , Room 543-745 Bannatyne Avenue, Winnipeg Manitoba R3E 0J9 ,","place":["Canada"]},{"name":"Clinical Microbiology, Diagnostic Services, Shared Health , MS673-820 Sherbrook Street, Winnipeg, Manitoba R3A 1R9 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5646-6454","authenticated-orcid":false,"given":"Heather J","family":"Adam","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba , Room 543-745 Bannatyne Avenue, Winnipeg Manitoba R3E 0J9 ,","place":["Canada"]},{"name":"Clinical Microbiology, Diagnostic Services, Shared Health , MS673-820 Sherbrook Street, Winnipeg, Manitoba R3A 1R9 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Poutanen","sequence":"additional","affiliation":[{"name":"Department of Microbiology, University Health Network\/Sinai Health , 1470-600 University Avenue, Toronto, Ontario M5G 1X5 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Baxter","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba , Room 543-745 Bannatyne Avenue, Winnipeg Manitoba R3E 0J9 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A","family":"Karlowsky","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba , Room 543-745 Bannatyne Avenue, Winnipeg Manitoba R3E 0J9 ,","place":["Canada"]},{"name":"Clinical Microbiology, Diagnostic Services, Shared Health , MS673-820 Sherbrook Street, Winnipeg, Manitoba R3A 1R9 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"McCracken","sequence":"additional","affiliation":[{"name":"National Microbiology Laboratory, Public Health Agency of Canada , 1015 Arlington Street, Winnipeg, Manitoba R3E 3M4 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George R","family":"Golding","sequence":"additional","affiliation":[{"name":"National Microbiology Laboratory, Public Health Agency of Canada , 1015 Arlington Street, Winnipeg, Manitoba R3E 3M4 ,","place":["Canada"]},{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba , Room 543-745 Bannatyne Avenue, Winnipeg Manitoba R3E 0J9 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George G","family":"Zhanel","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba , Room 543-745 Bannatyne Avenue, Winnipeg Manitoba R3E 0J9 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"2025082801313960800_dkaf221-B1","author":"WHO"},{"key":"2025082801313960800_dkaf221-B2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.diagmicrobio.2012.11.009","article-title":"Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes","volume":"75","author":"van Duin","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2025082801313960800_dkaf221-B3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"key":"2025082801313960800_dkaf221-B4","doi-asserted-by":"publisher","first-page":"823684","DOI":"10.3389\/fcimb.2022.823684","article-title":"Global threat of carbapenem-resistant Gram-negative bacteria","volume":"12","author":"Jean","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"2025082801313960800_dkaf221-B5","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1080\/14656566.2021.1904891","article-title":"Escalating antimicrobial resistance among Enterobacteriaceae: focus on carbapenemases","volume":"22","author":"Lynch","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"2025082801313960800_dkaf221-B6","doi-asserted-by":"publisher","first-page":"e0186922","DOI":"10.1128\/aem.01869-22","article-title":"Characterization of Escherichia coli and other Enterobacterales resistant to extended-spectrum cephalosporins isolated from dairy manure in Ontario, Canada","volume":"89","author":"Anderson","year":"2023","journal-title":"Appl Environ Microbiol"},{"key":"2025082801313960800_dkaf221-B7","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1128\/AAC.01591-05","article-title":"Outer membrane protein changes and efflux pump expression together may confer resistance to ertapenem in Enterobacter cloacae","volume":"50","author":"Szab\u00f3","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2025082801313960800_dkaf221-B8","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1128\/AAC.43.7.1669","article-title":"Roles of \u03b2-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae","volume":"43","author":"Mart\u00ednez-Mart\u00ednez","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"2025082801313960800_dkaf221-B9","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1086\/503264","article-title":"In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum \u03b2-lactamase","volume":"42","author":"Elliott","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2025082801313960800_dkaf221-B10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.molmed.2012.03.003","article-title":"Carbapenem resistance in Enterobacteriaceae: here is the storm!","volume":"18","author":"Nordmann","year":"2012","journal-title":"Trends Mol Med"},{"key":"2025082801313960800_dkaf221-B11","doi-asserted-by":"publisher","first-page":"S521","DOI":"10.1093\/cid\/ciz824","article-title":"Epidemiology and diagnostics of carbapenem resistance in Gram-negative bacteria","volume":"69","author":"Nordmann","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025082801313960800_dkaf221-B12","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1128\/AAC.01009-09","article-title":"Updated functional classification of beta-lactamases","volume":"54","author":"Bush","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2025082801313960800_dkaf221-B13","volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically\u2014Twelfth Edition: M07","author":"CLSI"},{"key":"2025082801313960800_dkaf221-B14","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing\u2014Thirty-Fourth Edition: M100","author":"CLSI"},{"key":"2025082801313960800_dkaf221-B15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3390\/microorganisms10020292","article-title":"Correlation between phenotypic and in silico detection of antimicrobial resistance in Salmonella enterica in Canada using Staramr","volume":"10","author":"Bharat","year":"2022","journal-title":"Microorganisms"},{"key":"2025082801313960800_dkaf221-B16","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1093\/jac\/dkaa345","article-title":"ResFinder 4.0 for predictions of phenotypes from genotypes","volume":"75","author":"Bortolaia","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2025082801313960800_dkaf221-B17","doi-asserted-by":"publisher","first-page":"124","DOI":"10.12688\/wellcomeopenres.14826.1","article-title":"Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications","volume":"3","author":"Jolley","year":"2018","journal-title":"Wellcome Open Res"},{"key":"2025082801313960800_dkaf221-B18","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1128\/AAC.01261-13","article-title":"Identification of 50 class D \u03b2-lactamases and 65 Acinetobacter-derived cephalosporinases in Acinetobacter spp","volume":"58","author":"P\u00e9richon","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2025082801313960800_dkaf221-B19","author":"ECDC"},{"key":"2025082801313960800_dkaf221-B20","doi-asserted-by":"publisher","first-page":"e0122024","DOI":"10.1128\/jcm.01220-24","article-title":"Characterization of carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa carrying multiple carbapenemase genes\u2014Antimicrobial Resistance Laboratory Network, 2018\u20132022","volume":"62","author":"Sabour","year":"2024","journal-title":"J Clin Microbiol"},{"key":"2025082801313960800_dkaf221-B21","doi-asserted-by":"publisher","first-page":"127249","DOI":"10.1016\/j.micres.2022.127249","article-title":"Global spread of carbapenem-resistant Enterobacteriaceae: epidemiological features, resistance mechanisms, detection and therapy","volume":"266","author":"Ma","year":"2023","journal-title":"Microbiol Res"},{"key":"2025082801313960800_dkaf221-B22","doi-asserted-by":"publisher","first-page":"e0000823","DOI":"10.1128\/cmr.00008-23","article-title":"Klebsiella pneumoniae carbapenemase variants: the new threat to global public health","volume":"36","author":"Ding","year":"2023","journal-title":"Clin Microbiol Rev"},{"key":"2025082801313960800_dkaf221-B23","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.1128\/AAC.01019-15","article-title":"Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance","volume":"59","author":"Pitout","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2025082801313960800_dkaf221-B24","doi-asserted-by":"publisher","first-page":"e0097522","DOI":"10.1128\/spectrum.00975-22","article-title":"Characterization of extensively drug-resistant (XDR) carbapenemase-producing Enterobacterales (CPE) in Canada from 2019 to 2020","volume":"10","author":"Bartoszko","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2025082801313960800_dkaf221-B25","doi-asserted-by":"publisher","first-page":"6787","DOI":"10.1128\/AAC.01359-16","article-title":"Results from the Canadian nosocomial infection surveillance program on carbapenemase-producing Enterobacteriaceae, 2010 to 2014","volume":"60","author":"Mataseje","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2025082801313960800_dkaf221-B26","doi-asserted-by":"publisher","first-page":"e00115-20","DOI":"10.1128\/CMR.00115-20","article-title":"New \u03b2-lactam\u2013\u03b2-lactamase inhibitor combinations","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"2025082801313960800_dkaf221-B27","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jmii.2021.02.001","article-title":"Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan","volume":"55","author":"Yang","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"2025082801313960800_dkaf221-B28","doi-asserted-by":"publisher","first-page":"e01951-19","DOI":"10.1128\/AAC.01951-19","article-title":"Meropenem-vaborbactam activity against carbapenem-resistant Enterobacterales isolates collected in U.S. hospitals during 2016 to 2018","volume":"64","author":"Castanheira","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025082801313960800_dkaf221-B29","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3892\/etm.2017.5485","article-title":"Mechanism for carbapenem resistance of clinical Enterobacteriaceae isolates","volume":"15","author":"Ye","year":"2018","journal-title":"Exp Ther Med"},{"key":"2025082801313960800_dkaf221-B30","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1128\/JCM.01263-11","article-title":"Characterization of ertapenem-resistant Enterobacter cloacae in a Taiwanese university hospital","volume":"50","author":"Yang","year":"2012","journal-title":"J Clin Microbiol"},{"issue":"Suppl 2","key":"2025082801313960800_dkaf221-B31","doi-asserted-by":"publisher","first-page":"ii2","DOI":"10.1093\/jac\/dkaf216","article-title":"Seventeen years of the CANWARD study (2007\u201323)","volume":"80","author":"Zhanel","year":"2025","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/Supplement_2\/ii54\/64140430\/dkaf221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/Supplement_2\/ii54\/64140430\/dkaf221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:31:44Z","timestamp":1756359104000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/Supplement_2\/ii54\/8241925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":31,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2025,8,28]]},"published-print":{"date-parts":[[2025,8,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf221","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,8,28]]}}}